Regular ArticleEstablishment and Characterization of Two Human Ovarian Clear Cell Adenocarcinoma Lines from Metastatic Lesions with Different Properties
References (0)
Cited by (51)
Moesin affects the plasma membrane expression and the immune checkpoint function of CD47 in human ovarian clear cell carcinoma
2024, Journal of Reproductive ImmunologyThe primary effect on the proteome of ARID1A-mutated ovarian clear cell carcinoma is downregulation of the mevalonate pathway at the post-transcriptional level
2016, Molecular and Cellular ProteomicsCitation Excerpt :We performed a complementary proteomics analysis to validate the effects of ARID1A knockout observed in OVCA429 in an alternative biological context. Wild-type ARID1A was reintroduced into the ARID1A-mutated OCCC cell line OVISE (38), which completely lacks expression of ARID1A protein (17), using a tetracycline-inducible construct (supplemental Fig. S3). This experimental approach was recently used to study the transcriptional effects of ectopic expression of wild-type ARID1A in OVISE cells (20).
Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions
2012, Neoplasia (United States)Clear cell carcinoma of the ovary: A review of the literature
2012, Gynecologic OncologyCitation Excerpt :The study by Gorai et al. supports this rationale. In this study, ovarian CCC cells exhibited resistance to cisplatin [89]. However, given the retrospective nature of our study and the others cited, firm conclusions on this relationship cannot be reached.
Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: A meta-analysis
2011, Gynecologic OncologyCitation Excerpt :One potential mechanism related to the poor overall survival in CCC may be insensitivity to platinum-based chemotherapy, which is also related to chemoresistance [36] relative to non-CCC [6,16,17,24,28,31,37]. For example, an in vitro study indicated that CCC cells exhibited resistance to platinum [38] and Sugiyama et al. reported that the response rate to platinum-based chemotherapy in patients with CCC was significantly lower than in patients with serous EOC (11.1% vs. 72.5%) [17]. Combination chemotherapy with platinum plus paclitaxel-based chemotherapy has been accepted as the standard regimen for EOC [39].